Lixisenatide in patients with type 2 diabetes and acute coronary syndrome

New England Journal of Medicine

Volumn 373, Issue 23, 2015, Pages 2247-2257

  Pfeffer, Marc A ^a   Claggett, Brian ^a   Diaz, Rafael ^b   Dickstein, Kenneth ^c   Gerstein, Hertzel C ^d   Køber, Lars V ^e   Lawson, Francesca C ^f   Ping, Lin ^f   Wei, Xiaodan ^f   Lewis, Eldrin F ^a   Maggioni, Aldo P ^g   McMurray, John J V ^h   Probstfield, Jeffrey L ⁱ   Riddle, Matthew C ^j   Solomon, Scott D ^a   Tardif, Jean Claude ^k  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Instituto Cardiovascular de Rosario   (Argentina)

^c UNIVERSITY OF BERGEN   (Norway)

^d MCMASTER UNIVERSITY   (Canada)

^e Rigshospitalet   (Denmark)

^f SANOFI   (France)

^g Research Center of the Italian Association of Hospital Cardiologists   (Italy)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k MONTREAL HEART INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIXISENATIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; ZP10A PEPTIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLERGIC REACTION; ANTISOCIAL PERSONALITY DISORDER; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG SAFETY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; GLYCEMIC CONTROL; HAZARD RATIO; HEART ARREST; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART RATE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; IMMUNOPATHOLOGY; INFECTION; INJURY; INTOXICATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MORBIDITY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DEFICIENCY; PANCREAS TUMOR; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE DISEASE; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; URINARY DYSFUNCTION; VASCULAR DISEASE; AGONISTS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; TREATMENT FAILURE;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PROPORTIONAL HAZARDS MODELS; TREATMENT FAILURE;

EID: 84948740668     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1509225     Document Type: Article

References (37)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
2. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
3. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
5. Gerstein HC, Miller ME, Ismail-Beigi F, et al. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet 2014; 384: 1936-41.
6. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.
7. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197-206.
8. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-36.
9. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092-5.
10. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014; 2: 843-51.
11. Diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Department of Health and Human Services, Center for Drug Evaluation and Research, 2008.
12. European Medicines Agency guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. London: Committee for Medicinal Products for Human Use, 2012.
13. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med 2013; 369: 1285-7.
14. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65.
15. Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009; 58: 975-83.
16. Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53: 501-10.
17. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109: 962-5.
18. Woo JS, Kim W, Ha SJ, et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013; 33: 2252-60.
19. Nathanson D, Ullman B, Löfström U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia 2012; 55: 926-35.
20. Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol 2014; 13: 142.
21. Smilowitz NR, Donnino R, Schwartzbard A. Glucagon-like peptide-1 receptor agonists for diabetes mellitus: a role in cardiovascular disease. Circulation 2014; 129: 2305-12.
22. Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G, Miossec P, Gerich JE. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebocontrolled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012; 35: 1225-31.
23. Bolli GB, Munteanu M, Dotsenko S, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med 2014; 31: 176-84.
24. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 2013; 36: 2489-96.
25. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-42.
26. Bentley-Lewis R, Aguilar D, Riddle MC, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J 2015; 169(5): 631-638.e7.
27. Yang F, Stewart M, Ye J, DeMets D. Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements. Diabetes Metab Syndr Obes 2015; 8: 315-25.
28. Jhund PS, McMurray JJV, Chaturvedi N, et al. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. Eur Heart J 2015; 36: 2463-9.
29. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015; 3: 356-66.
30. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-42.
31. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-41.
32. Barkoudah E, Skali H, Uno H, Solomon SD, Pfeffer MA. Mortality rates in trials of subjects with type 2 diabetes. J Am Heart Assoc 2012; 1: 8-15.
33. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-24.
34. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-67.
35. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35: Suppl 1: S11-63.
36. Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2015; 132: 691-718.
37. Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-54.